Kimberly-Clark — the maker of Huggies and Kleenex — is acquiring Kenvue, parent company of Band-Aid and Tylenol, in a $48.7 billion cash-and-stock deal that will reshape the global consumer goods landscape.
Kenvue shares jumped 15 percent in early trading Monday, while Kimberly-Clark fell 12 percent following the announcement.
The merger will unite more than ten billion-dollar brands under one roof, including household staples such as Huggies, Kleenex, Tylenol, and Band-Aid. The combined company projects 2025 net revenue of about $32 billion and adjusted EBITDA of roughly $7 billion, according to a joint statement.
The transaction — one of 2025’s largest Wall Street deals — is expected to close in the second half of 2026.
Kimberly-Clark CEO Mike Hsu described the acquisition as the company’s “next step” toward a higher-margin future. The move follows a broader trend of consolidation among consumer giants adapting to tariffs, inflation, and shifting spending habits, explored in The AI Shake-Up: Which Jobs Are Most at Risk and 4th Quarter Money Moves: How to End 2025 Strong.
Kenvue spun off from Johnson & Johnson in 2023 in the company’s biggest restructuring in nearly 140 years. Since its IPO, shares have fallen almost 35 percent, closing last week near $14 per share for a market cap of $27 billion.
The brand also faced scrutiny after unsubstantiated claims linked Tylenol use in pregnancy to autism — assertions medical experts widely dismissed. Kenvue strongly denied the allegations, emphasizing the product’s safety and long history of use among over 100 million Americans each year.
Kimberly-Clark has been reshaping its portfolio amid higher input costs and changing consumer trends. Earlier this year, it exited private-label diaper production for Costco to focus on premium brands and sold a majority stake in its international tissue business to Brazil’s Suzano, forming a joint venture aimed at stabilizing margins.
Once the Kenvue deal closes, Kimberly-Clark will add over-the-counter health brands like Sudafed and Pepcid, intensifying competition with Procter & Gamble — whose portfolio includes Pepto-Bismol and Vicks. P&G, however, remains far larger, with a $350 billion market cap.
The companies expect $1.9 billion in cost synergies within three years of closing. Three Kenvue board members will join Kimberly-Clark’s board, and Hsu will remain chairman and CEO.
Kenvue chair Larry Merlo called the merger “the best path forward for our shareholders and stakeholders.” The acquisition follows similar consolidation plays, such as Mars’ purchase of Kellanova and Ferrero’s acquisition of W.K. Kellogg earlier this year — both part of a broader realignment of legacy consumer brands.
Kimberly-Clark’s move to acquire Kenvue highlights a growing truth in consumer goods: scale is survival. As cost pressures, tariffs, and changing consumer habits reshape the industry, consolidation — not expansion — may be the key to staying competitive.
Read more insights on consumer-market strategy in Is Your Money Working as Hard as You Do?.
View All News